Cargando…

Prediction of Transporter‐Mediated Drug‐Drug Interactions for Baricitinib

Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, undergoes active renal tubular secretion. Baricitinib was not predicted to inhibit hepatic and renal uptake and efflux drug transporters, based on the ratio of the unbound maximum eliminating‐organ inlet concentration and the in vitro ha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Posada, Maria M., Cannady, Ellen A., Payne, Christopher D., Zhang, Xin, Bacon, James A., Pak, Y. Anne, Higgins, J. William, Shahri, Nazila, Hall, Stephen D., Hillgren, Kathleen M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402191/ https://www.ncbi.nlm.nih.gov/pubmed/28749581 http://dx.doi.org/10.1111/cts.12486

Ejemplares similares

In Vitro and Clinical Evaluations of the Drug-Drug Interaction Potential of a Metabotropic Glutamate 2/3 Receptor Agonist Prodrug with Intestinal Peptide Transporter 1
por: Pak, Y. Anne, et al.
Publicado: (2017)

CYP‐mediated drug–drug interactions with evacetrapib, an investigational CETP inhibitor: in vitro prediction and clinical outcome
por: Cannady, Ellen A., et al.
Publicado: (2015)

DFT study on the structural and chemical properties of Janus kinase inhibitor drug Baricitinib
por: Sonia, Chiging, et al.
Publicado: (2022)

Expert-Augmented Computational Drug Repurposing Identified Baricitinib as a Treatment for COVID-19
por: Smith, Daniel P., et al.
Publicado: (2021)

Renal drug transporters and their significance in drug–drug interactions
por: Yin, Jia, et al.
Publicado: (2016)

Assessing the Solubility of Baricitinib and Drug Uptake in Different Tissues Using Absorption and Fluorescence Spectroscopies
por: Mohammadi-Meyabadi, Roya, et al.
Publicado: (2022)

Oral Bioactive Self-Nanoemulsifying Drug Delivery Systems of Remdesivir and Baricitinib: A Paradigmatic Case of Drug Repositioning for Cancer Management
por: Kazi, Mohsin, et al.
Publicado: (2023)

Metabolism, Transport and Drug–Drug Interactions of Silymarin
por: Xie, Ying, et al.
Publicado: (2019)

Transporter-Mediated Drug–Drug Interactions with Oral Antidiabetic Drugs
por: Klatt, Sabine, et al.
Publicado: (2011)

Application of Baricitinib in Dermatology
por: Zhang, Jingya, et al.
Publicado: (2022)

Safety and Efficacy of Baricitinib in Patients Receiving Conventional Synthetic Disease-Modifying Antirheumatic Drugs or Corticosteroids
por: van Vollenhoven, Ronald, et al.
Publicado: (2018)

Tofacitinib and Baricitinib Are Taken up by Different Uptake Mechanisms Determining the Efficacy of Both Drugs in RA
por: Amrhein, Jan, et al.
Publicado: (2020)

Clinical Studies on Drug–Drug Interactions Involving Metabolism and Transport: Methodology, Pitfalls, and Interpretation
por: Tornio, Aleksi, et al.
Publicado: (2019)

Physiologically‐Based Pharmacokinetic Modeling of Atorvastatin Incorporating Delayed Gastric Emptying and Acid‐to‐Lactone Conversion
por: Morse, Bridget L., et al.
Publicado: (2019)

Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment
por: Fleischmann, Roy, et al.
Publicado: (2017)

Baricitinib and primary biliary cholangitis
por: Gordon, Stuart C., et al.
Publicado: (2021)

Baricitinib for the treatment of rheumatoid arthritis
por: Urits, Ivan, et al.
Publicado: (2020)

Drug Interactions of Metformin Involving Drug Transporter Proteins
por: Pakkir Maideen, Naina Mohamed, et al.
Publicado: (2017)

Drug-Drug Interactions at Organic Cation Transporter 1
por: Zhou, Shiwei, et al.
Publicado: (2021)

Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment
por: Schiff, Michael, et al.
Publicado: (2017)

Baricitinib for the Treatment of Alopecia Areata
por: Freitas, Egídio, et al.
Publicado: (2023)

Drug–nutrient interactions: discovering prescription drug inhibitors of the thiamine transporter ThTR-2 (SLC19A3)
por: Vora, Bianca, et al.
Publicado: (2020)

Optimization of a drug transporter probe cocktail: potential screening tool for transporter‐mediated drug–drug interactions
por: Stopfer, Peter, et al.
Publicado: (2018)

HTLV-2 infection still prevalent among older injecting drug users in Stockholm, Sweden – indications of limited spread to the younger generation
por: Malm, Kerstin, et al.
Publicado: (2011)

Evacetrapib: in vitro and clinical disposition, metabolism, excretion, and assessment of drug interaction potential with strong CYP3A and CYP2C8 inhibitors
por: Cannady, Ellen A, et al.
Publicado: (2015)

Drugs in COVID‐19 Clinical Trials: Predicting Transporter‐Mediated Drug‐Drug Interactions Using In Vitro Assays and Real‐World Data
por: Yee, Sook Wah, et al.
Publicado: (2021)

Using Positron Emission Tomography to Study Transporter-Mediated Drug–Drug Interactions in Tissues
por: Wulkersdorfer, B, et al.
Publicado: (2014)

Endogenous Biomarkers for SLC Transporter-Mediated Drug-Drug Interaction Evaluation
por: Li, Yang, et al.
Publicado: (2021)

Transport and Permeation Properties of Dapivirine: Understanding Potential Drug-Drug Interactions
por: Zheng, Ruohui, et al.
Publicado: (2022)

Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis
por: Taylor, Peter C., et al.
Publicado: (2019)

Maternal use of drug substrates of placental transporters and the effect of transporter-mediated drug interactions on the risk of congenital anomalies
por: Daud, Aizati N. A., et al.
Publicado: (2017)

A Metabolomics Approach for Predicting OATP1B-Type Transporter-Mediated Drug–Drug Interaction Liabilities
por: Li, Yang, et al.
Publicado: (2022)

Interaction of Remdesivir with Clinically Relevant Hepatic Drug Uptake Transporters
por: Nies, Anne T., et al.
Publicado: (2021)

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
por: Kalil, Andre C., et al.
Publicado: (2020)

P-glycoprotein- and organic anion-transporting polypeptide-mediated transport of periplocin may lead to drug–herb/drug–drug interactions
por: Liang, Sheng, et al.
Publicado: (2014)

15. Eosinophilic pneumonitis secondary to baricitinib
por: Yein, Khin, et al.
Publicado: (2019)

Treatment of severe alopecia areata with baricitinib
por: Olamiju, Brianna, et al.
Publicado: (2019)

Baricitinib: Two Birds with One Stone
por: Saj, Fen, et al.
Publicado: (2022)

Interaction of Hydroxychloroquine with Pharmacokinetically Important Drug Transporters
por: Weiss, Johanna, et al.
Publicado: (2020)

Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter
por: Moss, Darren M., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_kpusr5ura0j526rthh4n47fpcu